Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy
Author:
Affiliation:
1. Alligator Bioscience AB, Sweden
2. Department of Immunotechnology, Lund University, Lund, Sweden
Funder
funded
Publisher
Informa UK Limited
Subject
Clinical Biochemistry,Drug Discovery,Pharmacology
Link
https://www.tandfonline.com/doi/pdf/10.1080/14712598.2021.1934446
Reference159 articles.
1. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2. The future of cancer immunotherapy: microenvironment-targeting combinations
3. The Immune Revolution: A Case for Priming, Not Checkpoint
4. Oncology Meets Immunology: The Cancer-Immunity Cycle
5. Kick-starting the cancer-immunity cycle by targeting CD40
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors;Immunotherapy;2024-09-12
2. Next-generation CD40 agonists for cancer immunotherapy;Expert Opinion on Biological Therapy;2024-05-03
3. Fcγ-Receptor-Independent Controlled Activation of CD40 Canonical Signaling by Novel Therapeutic Antibodies for Cancer Therapy;Antibodies;2024-04-18
4. The present and future of bispecific antibodies for cancer therapy;Nature Reviews Drug Discovery;2024-03-06
5. i-shaped antibody engineering enables conformational tuning of biotherapeutic receptor agonists;Nature Communications;2024-01-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3